Search Results 641-650 of 12825 for hypercoagulable
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival ...
The purpose of this study is to determine how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has ...
About this study. This study will compare the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a ...
To diagnose DVT, your health care provider will do a physical exam and ask questions about your symptoms. The provider will check the legs for swelling, ...
Hematology — Learn about innovative diagnosis and treatment options for blood diseases, including cancers, at Mayo Clinic.
The purpose of this study is to assess the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose ...
Lymphoma is a diversified disease with outcomes differing upon the types and subtypes of lymphoma as well as treatment modalities used. Fertility outcomes in ...
The purpose of this study is to evaluate the safety and tolerability of ATV1601 in participants with HHT. Participation eligibility. Participant eligibility ...
The purpose of this study is to compare the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.